Prof Steven Myint appointed as BTG's first Chief Medical Officer

20-Feb-2007

BTG plc announced that it has appointed Prof Steven Myint as Chief Medical Officer. Prof Myint has most recently served as Dean of Medicine and Professor of Medicine and microbiology at the University of Surrey, UK. From 2003-2005 he was Group Medical Director, Oncology/Biologicals at GlaxoSmithKline, and prior to that held a number of senior medical roles in GlaxoSmithKline and SmithKline Beecham Pharmaceuticals with responsibility for therapeutic areas including oncology, psychiatry/neurosciences and biological medicines He is a member of a number of medical advisory bodies and government and international committees.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Flame retardant ban reduces exposures in pregnant women

Peregrine Enters Contract Negotiations With U.S. DTRA for Hemorrhagic Fevers - U.S. Department of Defense Agency Has Selected Peregrine for a Multi-Year Award That Could Total $44.5 Million Pending Successful Contract Negotiations

Food safety in Europe - who is responsible for what? - BfR publishes 2. completely revised edition of the EU Food Safety Almanac

SemBioSys signs contract manufacturing agreement for plant-produced insulin with Cangene

Cellzome Achieves Clinical Candidate Milestone from Inflammation Alliance with GlaxoSmithKline

Bionomics BNC105 cancer clinical trials reach key milestones - Clinical program to be expanded

Crucell to sell Rhein Biotech GmbH to Dynavax

Active Biotech's nomination committee proposes election of an additional new board member

ITI Life Sciences licenses technology to Cognia to develop a database product to enhance drug discovery and development

Delisting of Merck Serono shares expected on July 18, 2007 - Squeeze Out Successfully Completed

Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease

MediGene Acquires Patents on Anti-Cancer Drugs Under Development - License agreements with the University of Chicago guarantee exclusive worldwide rights to the most important groups of patents in the field of oncolytic Herpes Simplex Viruses (HSV)